Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

About Tsime

Tsime has the license for the cultivation of medicinal grade cannabis on a farm.On July 17th, 2020, Tsime was acquired by Wuhan General Group. The terms of the transaction were not disclosed.

Tsime Headquarters Location


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Tsime

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tsime is included in 1 Expert Collection, including Cannabis.



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Latest Tsime News

Wuhan General Group Signs MOA for the Acquisition of Tsime Pharmaceuticals (PTY) Limited

Jul 17, 2020

CAPE TOWN, SA / ACCESSWIRE / July 17, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK: WUHN ) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective July 16th, 2020, it has signed a Memorandum of Agreement to pursue the Acquisition (the “Transaction”) of Tsime Pharmaceuticals and Medicinal Supplies (Pty) Ltd (“Tsime”). Tsime will become a subsidiary of MJ Medtech. The Tsime license grants the ability to cultivate, extract and process medicinal cannabis and sell the commodity for medicinal, scientific and any other legal purpose. The Transaction is anticipated to close within 90 days. Located in the Kingdom of Lesotho in Southern Africa, Tsime has the license for the cultivation of 3 hectares of medicinal grade cannabis on a farm with a land area covering 32 hectares or 80 acres. The acquisition is extremely strategic for Wuhan. Having its own cultivation, extraction and processing medicinal cannabis operation, is key to driving research and the manufacturing of CBD by-products. Lesotho offers remarkable advantages: Groundwater availability and soil quality: Excellent economic growing conditions. Abundant land: Mountainous hectares allows for large, open-air crops. Elevation and protection: Average elevation of Lesotho is 2255 meters or 7,090 feet. Labour: Low cost experienced growers and readily available local workforce. Government: Pro cannabis with a low regulatory burden. Willem Jonker, speaking on behalf of the Medigrow Africa Group, said: ” M2Bio Sciences already sources top-quality coffee from Tanzania, and will now be able to control the production of top-quality cannabis from Lesotho for their product range. The world will be impressed by the results. “ “Cannabis cultivation was off our radar and low on the priority list until recently. The big and much-needed shakeout in the cannabis sector has offered up tremendous opportunities for Wuhan and its shareholders. As many companies have been forced to leave the battlefield badly wounded, some mortally, we enter the arena unscathed and at a fraction of the costs. We plan to expand our relationship considerably in the coming months with Willem and Medigrow Africa. Furthermore, we are very proud to contribute to the economic development of Lesotho through this Transaction. The grass is greener in Africa! “ said Jeff Robinson, Chief Executive Officer of Wuhan General Group. A summary of the transaction and timeline for production ramp-up will be made available after the closing of the Transaction. About Medigrow Africa Medigrow Africa is a formal network of legal African cannabis growers producing international-grade medical cannabis products for global distribution. Medigrow Africa is the largest collective of African cannabis businesses and it dominates the African medicinal cannabis industry. Medigrow benefits from lower labour, land, and regulatory costs. Also, Medigrow is in the lower quartile of production costs and the upper quartile of profitability globally. About Wuhan General Group, Inc./ M2Bio Sciences, Inc Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”. For further information: Follow us on Facebook: Forward-Looking Statements: Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements. SOURCE: Wuhan General Group, Inc. View source version on

  • What is Tsime's latest funding round?

    Tsime's latest funding round is Acquired.

  • Who are the investors of Tsime?

    Investors of Tsime include Wuhan General Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.